Javascript must be enabled to continue!
Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857 and the Inhibitory Effects on Ovarian Cancer Cell Proliferation
View through CrossRef
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD
in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA)
LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for
clinical diagnosis and treatment of ovarian cancer. In the study, the ovarian cancer cell lines (BT 549)
were rolled into a control group (normal culture-defined as BT549/NC) and a response group
(transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells). The
expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer
cells were analyzed and compared. The results showed that the YAP-TEAD expression rate was the
highest in Bt549 cells; the YAP content grade (0.18) in BT 549-YAP cells was lower than BT 549/NC
(0.2) after transfection (P< 0.05); and the apoptotic rate of the response group (80%) was higher than
that of the control group (25%) after the intervention. With the extension of culture time, the expression
of CCN1 mRNA decreased (P< 0.05), and CCN2 mRNA increased (P< 0.05). After 12, 24, 36, and 48
hours, the apoptosis rate of the reaction group at different time points was higher than that of the control
group (P< 0.01). When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549-
YAP cells was weakened compared with BT 549/NC and parental cells. It was concluded that the noncoding
RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway
to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and
promoting cell apoptosis.
Title: Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857
and the Inhibitory Effects on Ovarian Cancer Cell Proliferation
Description:
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD
in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA)
LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for
clinical diagnosis and treatment of ovarian cancer.
In the study, the ovarian cancer cell lines (BT 549)
were rolled into a control group (normal culture-defined as BT549/NC) and a response group
(transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells).
The
expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer
cells were analyzed and compared.
The results showed that the YAP-TEAD expression rate was the
highest in Bt549 cells; the YAP content grade (0.
18) in BT 549-YAP cells was lower than BT 549/NC
(0.
2) after transfection (P< 0.
05); and the apoptotic rate of the response group (80%) was higher than
that of the control group (25%) after the intervention.
With the extension of culture time, the expression
of CCN1 mRNA decreased (P< 0.
05), and CCN2 mRNA increased (P< 0.
05).
After 12, 24, 36, and 48
hours, the apoptosis rate of the reaction group at different time points was higher than that of the control
group (P< 0.
01).
When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549-
YAP cells was weakened compared with BT 549/NC and parental cells.
It was concluded that the noncoding
RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway
to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and
promoting cell apoptosis.
Related Results
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract
The Hippo signalling pathway plays a major role in organ growth regulation and tumorigenesis. By sensing contact inhibition, the central kinase network of t...
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract
TEAD transcription factors have emerged as clinically validated targets for Hippo-altered cancers, e.g. mesothelioma driven by NF2 inactivation/deficiency. ...
Abstract A45: In silico drug discovery targeting Hippo pathway and YAP-TEAD protein-protein interactions for small-molecule anticancer agent
Abstract A45: In silico drug discovery targeting Hippo pathway and YAP-TEAD protein-protein interactions for small-molecule anticancer agent
Abstract
The Hippo pathway is one of the important pathways regulating tissue growth and proliferation. Dysregulation of this pathway can result in overgrowth of phe...
Abstract 1015: Head and neck cancer expression of YAP65: A novel oncogene
Abstract 1015: Head and neck cancer expression of YAP65: A novel oncogene
Abstract
Yes-associated protein (YAP), a transcription coactivator associated with maintaining tissue size, is reported as an oncogene in many types of cancer includ...
Age dependent endothelial responses to pneumonia-induced Acute Lung Injury
Age dependent endothelial responses to pneumonia-induced Acute Lung Injury
Objective: Children with Pediatric Acute Respiratory Distress Syndrome (PARDS) have better outcomes than adults with ARDS. Animal studies suggest that the reasons for improved outc...
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
L'ostéosarcome (OS) est la tumeur osseuse primitive maligne la plus fréquente chez les enfants et les adolescents dont le pronostic reste mauvais, surtout lorsque des métastases so...
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Abstract
YAP activation in cancer is linked to poor outcomes, making it an attractive therapeutic target. Previous research focused on blocking the interaction of...
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
ABSTRACT
YAP activation in cancer is linked to poor outcomes, making it an attractive therapeutic target. Previous research focused on blocking the interaction of Y...

